Pfizer Inc. (NYSE:PFE) Shares Sold by Tidemark LLC

Tidemark LLC lessened its holdings in shares of Pfizer Inc. (NYSE:PFE) by 32.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,874 shares of the biopharmaceutical company’s stock after selling 1,371 shares during the quarter. Tidemark LLC’s holdings in Pfizer were worth $83,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the business. China Universal Asset Management Co. Ltd. acquired a new position in shares of Pfizer during the 1st quarter valued at about $315,000. Edgestream Partners L.P. acquired a new position in Pfizer in the 1st quarter valued at about $243,000. Hillsdale Investment Management Inc. grew its stake in shares of Pfizer by 111.3% in the 1st quarter. Hillsdale Investment Management Inc. now owns 3,132 shares of the biopharmaceutical company’s stock valued at $87,000 after buying an additional 1,650 shares during the period. Rockport Wealth LLC purchased a new stake in Pfizer in the first quarter valued at $294,000. Finally, O Shaughnessy Asset Management LLC lifted its holdings in shares of Pfizer by 7.1% in the 1st quarter. O Shaughnessy Asset Management LLC now owns 317,495 shares of the biopharmaceutical company’s stock worth $8,810,000 after acquiring an additional 20,950 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on PFE. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and lifted their price objective for the company from $28.00 to $34.00 in a research note on Wednesday, August 7th. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research note on Wednesday, October 23rd. Sanford C. Bernstein assumed coverage on shares of Pfizer in a research report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price target on the stock. Wolfe Research began coverage on shares of Pfizer in a research note on Friday. They set an “underperform” rating and a $25.00 target price on the stock. Finally, Wells Fargo & Company raised their price target on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, five have given a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer currently has an average rating of “Moderate Buy” and an average target price of $32.92.

Pfizer Trading Up 0.2 %

NYSE PFE opened at $24.84 on Monday. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The company has a market capitalization of $140.77 billion, a price-to-earnings ratio of 33.51, a price-to-earnings-growth ratio of 0.79 and a beta of 0.67. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The firm’s fifty day moving average price is $28.64 and its 200 day moving average price is $28.67.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.64 by $0.42. The firm had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. Pfizer’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.17) EPS. On average, sell-side analysts expect that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be given a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 6.76%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s dividend payout ratio (DPR) is presently 227.03%.

Insider Buying and Selling at Pfizer

In other news, Director Scott Gottlieb acquired 1,000 shares of the stock in a transaction that occurred on Wednesday, October 30th. The shares were purchased at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the transaction, the director now directly owns 10,000 shares in the company, valued at approximately $282,400. This represents a 11.11 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. 0.06% of the stock is owned by company insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.